Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash from Financing Activities (2019 - 2025)

Pulmonx (LUNG) has disclosed Cash from Financing Activities for 7 consecutive years, with $181000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 60.57% to $181000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $840000.0, a 36.27% decrease, with the full-year FY2024 number at $1.4 million, down 93.63% from a year prior.
  • Cash from Financing Activities was $181000.0 for Q3 2025 at Pulmonx, up from -$67000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $20.7 million in Q1 2023 to a low of -$67000.0 in Q2 2025.
  • A 5-year average of $1.6 million and a median of $181000.0 in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 10015.38% in 2022, then crashed 204.55% in 2025.
  • Pulmonx's Cash from Financing Activities stood at $150000.0 in 2021, then tumbled by 55.33% to $67000.0 in 2022, then tumbled by 74.63% to $17000.0 in 2023, then skyrocketed by 264.71% to $62000.0 in 2024, then soared by 191.94% to $181000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Cash from Financing Activities are $181000.0 (Q3 2025), -$67000.0 (Q2 2025), and $664000.0 (Q1 2025).